1 – 14 of 14
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
(
- Contribution to journal › Article
- 2020
-
Mark
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-up
(
- Contribution to journal › Article
- 2018
-
Mark
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX)
(
- Contribution to journal › Article
-
Mark
Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53
(
- Contribution to journal › Article
-
Mark
EURO-B.O.S.S. : A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma
(
- Contribution to journal › Article
- 2017
-
Mark
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib : An exploratory analysis of a randomized clinical trial
(
- Contribution to journal › Article
-
Mark
The Scandinavian Sarcoma Group Central Register : 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma
(
- Contribution to journal › Article
- 2016
-
Mark
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
(
- Contribution to journal › Article
-
Mark
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
(
- Contribution to journal › Article
- 2015
-
Mark
Referral patterns, treatment and outcome of high-grade malignant bone sarcoma in Scandinavia-SSG Central Register 25 years' experience.
(
- Contribution to journal › Article
-
Mark
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection.
(
- Contribution to journal › Article
-
Mark
Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.
(
- Contribution to journal › Article
-
Mark
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.
(
- Contribution to journal › Scientific review
-
Mark
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
(
- Contribution to journal › Article